Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals

Diagnostic Microbiology and Infectious Disease

Volumn 35, Issue 1, 1999, Pages 81-88

  Deshpande, Lalitagauri M ^a   Diekema, Daniel J ^a,b   Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

^b Medical Microbiology Division   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINAFLOXACIN; CLINDAMYCIN; IMIPENEM; LEVOFLOXACIN; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HOSPITAL INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; UNITED STATES;

EID: 0033199556     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(99)00020-6     Document Type: Article

References (18)

1. Barry A.L., Fuchs P.C., Brown S.D. In vitro activities of five fluoroquinolone compounds against strains of Streptococcus pneumoniae with resistance to other antimicrobial agents. Antimicrob Agents Chemother. 40:1996;2431-2433.
2. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother. 40:1997;639-651.
3. Bochud P., Calandra T., Francioli P. Bacteremia due to viridans streptococci in neutropenic patients A review . Am J Med. 97:1994;256-264.
4. Cohen M.A., Huband M.D., Gage J.W., Yoder S.L., Roland G.E., Gracheck S.J. In vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin. J Antimicrob Chemother. 40:1997;205-211.
5. Cohen M.A., Yoder S.L., Huband M.D., Roland G.E., Courtney C.L. In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci. Antimicrob Agents Chemother. 39:1995;2123-2127.
6. Cormican M.G., Jones R.N. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, flerofloxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria. J Antimicrob Chemother. 36:1995;431-434.
7. Coronado V., Gaynes R., Edwards J. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the US. Infect Control Hosp Epidemiol. 16:1995;71-75.
8. Ednie L.M., Jacobs M.R., Appelbaum P.C. Comparative activities of clinafloxacin against gram-positive and -negative bacteria. Antimicrob Agents Chemother. 42:1998;1269-1273.
9. Fuchs P.C., Barry A.L., Brown S.D. In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American Centers. Antimicrob Agents Chemother. 42:1998;1274-1277.
10. Goldstein F.W., Acar J.F. Epidemiology of quinolone resistance Europe and North and South America . Drugs. 49:(Suppl 2):1995;36-42.
11. Harrington G.D., Zarins L.T., Ramsey M.A., Bradley S.F., Kauffman C.A. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin. Diagn Microbiol Infect Dis. 21:1995;27-31.
12. Jones R.N. Important and emerging beta-lactamase mediated resistances in hospital-based pathogens The Amp C enzymes . Diagn Microbiol Infect Dis. 31:1998;461-466.
13. Jones R.N., Johnson D.M. Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD-127391) and flerofloxacin (RO 23-56240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates. Diagn Microbiol Infect Dis. 21:1995;209-213.
14. Methods for dilution antimicrobial tests for bacteria that grow aerobically. Approved standard M7-A4. 1997;National Committee for Clinical Laboratory Standards, Wayne, PA.
15. th ed. M11-A4. Wayne, PA: National Committee for Clinical Laboratory Standards.
16. Performance standards for antimicrobial susceptibility testing. Supplemental tables, M100-S8. 1998;National Committee for Clinical Laboratory Standards, Wayne, PA.
17. Philippon A., Arlet G., Lagrange P.H. Origin and impact of plasmid-mediated extended spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis. 13:(S1):1994;17-29.
18. Shonekan D., Handwerger S., Mildvan D. Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against gram-positive bacteria. J Antimicrob Chemother. 39:1997;405-409.